跳至主要内容
临床试验/DRKS00011266
DRKS00011266
招募中
1 期

AP-IS: Lung cancer, Ablative high Precision radiotherapy and the Immune System: Evaluation of the immune-modulatory effects of stereotactic body radiation therapy (SBRT) of pulmonary lesions - L-AP-IS

niversitätsklinikum Freiburg, Klinik für Strahlenheilkunde0 个研究点目标入组 75 人2017年1月10日

概览

阶段
1 期
干预措施
未指定
疾病 / 适应症
C34
发起方
niversitätsklinikum Freiburg, Klinik für Strahlenheilkunde
入组人数
75
状态
招募中
最后更新
去年

概览

简要总结

暂无简介。

注册库
who.int
开始日期
2017年1月10日
结束日期
待定
最后更新
去年
研究类型
Interventional
性别
All

研究者

发起方
niversitätsklinikum Freiburg, Klinik für Strahlenheilkunde

入排标准

入选标准

  • Primary or recurrent non\-metastatic NSCLC or
  • Solitary or oligometastasic pulmonary metastasis of otherwise controlled malignant
  • Lesions confirmed by either histology or cytology or clear imaging signs of malignant tumors
  • Patient scheduled and eligible for SBRT with curative intention
  • Whole body FDG\-PET scan \+ WB\-CT or CT of chest and upper abdomen
  • Written informed consent must be given according to ICH/GCP, and national/local regulations
  • Adequate birth control measures during the study treatment period

排除标准

  • Other active or significantly bone marrow suppressing malignancy
  • WHO performance status \< 2
  • Prior radiotherapy to chest and/or mediastinum within 3 months before the start of SBRT
  • Chemotherapy and/or targeted treatment within 3 months before the start of SBRT
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow\-up schedule
  • Pregnancy

结局指标

主要结局

未指定

相似试验